You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMetixene
Accession NumberDB00340  (APRD01101)
TypeSmall Molecule
GroupsApproved
DescriptionMetixene (or methixene) is a anticholinergic used as an antiparkinsonian agent.
Structure
Thumb
Synonyms
Methixen
Methixene
Metisene
Metixeno
Metixenum
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
CholinfallNot Available
MethixartNot Available
TremarilNot Available
TremaritNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Metixene hydrochloride
Thumb
  • InChI Key: RSXZRFHNNTTWCB-UHFFFAOYNA-N
  • Monoisotopic Mass: 345.13179817
  • Average Mass: 345.929
DBSALT000602
Categories
UNII32VY6L26ZW
CAS number4969-02-2
WeightAverage: 309.468
Monoisotopic: 309.155120431
Chemical FormulaC20H23NS
InChI KeyInChIKey=MJFJKKXQDNNUJF-UHFFFAOYSA-N
InChI
InChI=1S/C20H23NS/c1-21-12-6-7-15(14-21)13-18-16-8-2-4-10-19(16)22-20-11-5-3-9-17(18)20/h2-5,8-11,15,18H,6-7,12-14H2,1H3
IUPAC Name
1-methyl-3-(9H-thioxanthen-9-ylmethyl)piperidine
SMILES
CN1CCCC(CC2C3=CC=CC=C3SC3=CC=CC=C23)C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as thioxanthenes. These are organic polycyclic compounds containing a thioxanthene moiety, which is an aromatic tricycle derived from xanthene by replacing the oxygen atom with a sulfur atom.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzothiopyrans
Sub Class1-benzothiopyrans
Direct ParentThioxanthenes
Alternative Parents
Substituents
  • Thioxanthene
  • Diarylthioether
  • Aralkylamine
  • Benzenoid
  • Piperidine
  • Tertiary aliphatic amine
  • Tertiary amine
  • Azacycle
  • Thioether
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationUsed for the symptomatic treatment of parkinsonism.
PharmacodynamicsMetixene is a tertiary antimuscarinic with actions similar to those of atropine; it also has antihistaminic and direct antispasmodic properties. It is used for the symptomatic treatment of parkinsonism, including the alleviation of the extrapyramidal syndrome induced by other drugs such as phenothiazines, but, like other antimuscarinics, it is of no value against tardive dyskinesias. Metixene has been discontinued.
Mechanism of actionParkinsonism is thought to result from an imbalance between the excitatory (cholinergic) and inhibitory (dopaminergic) systems in the corpus striatum. The mechanism of action of centrally active anticholinergic drugs such as metixene is considered to relate to competitive antagonism of acetylcholine at muscarinic receptors in the corpus striatum, which then restores the balance.
Related Articles
AbsorptionAbsorbed in the gastrointestinal tract following oral administration, however the extent of absorption is not known.
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Hepatic. Metabolism occurs via sulfoxydation and N-demethylation.

Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicitySigns of overdose include dilated and sluggish pupils, warm, dry skin, facial flushing, decreased secretions of the mouth, pharynx, nose, and bronchi, foul-smelling breath, elevated temperature, tachycardia, cardiac arrhythmias, decreased bowel sounds, urinary retention, delirium, disorientation, anxiety, hallucinations, illusions, confusion, incoherence, agitation, hyperactivity, ataxia, loss of memory, paranoia, combativeness, and seizures.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9825
Blood Brain Barrier+0.995
Caco-2 permeable+0.7863
P-glycoprotein substrateSubstrate0.81
P-glycoprotein inhibitor IInhibitor0.51
P-glycoprotein inhibitor IIInhibitor0.8379
Renal organic cation transporterInhibitor0.8034
CYP450 2C9 substrateNon-substrate0.7575
CYP450 2D6 substrateSubstrate0.7452
CYP450 3A4 substrateNon-substrate0.5709
CYP450 1A2 substrateNon-inhibitor0.8941
CYP450 2C9 inhibitorNon-inhibitor0.9516
CYP450 2D6 inhibitorInhibitor0.9146
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.951
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6914
Ames testNon AMES toxic0.8216
CarcinogenicityNon-carcinogens0.9644
BiodegradationNot ready biodegradable0.973
Rat acute toxicity2.4059 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.6823
hERG inhibition (predictor II)Inhibitor0.8044
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Novartis pharmaceuticals corp
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateLiquid
Experimental Properties
PropertyValueSource
melting point< 25 °CPhysProp
boiling point173 °C at 7.00E-02 mm HgPhysProp
water solubilitySoluble as HCl saltNot Available
logP4.7Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.000102 mg/mLALOGPS
logP5.51ALOGPS
logP5.06ChemAxon
logS-6.5ALOGPS
pKa (Strongest Basic)9.34ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area3.24 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity97.17 m3·mol-1ChemAxon
Polarizability35.67 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis ReferenceNot Available
General References
  1. Link [Link]
External Links
ATC CodesN04AA03
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
1,10-PhenanthrolineThe therapeutic efficacy of Metixene can be decreased when used in combination with 1,10-Phenanthroline.
AclidiniumAclidinium may increase the anticholinergic activities of Metixene.
AclidiniumThe risk or severity of adverse effects can be increased when Metixene is combined with Aclidinium.
AlfentanilThe risk or severity of adverse effects can be increased when Metixene is combined with Alfentanil.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Metixene is combined with Alphacetylmethadol.
AmbenoniumThe therapeutic efficacy of Metixene can be decreased when used in combination with Ambenonium.
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Metixene.
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Metixene.
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Metixene.
BenactyzineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Metixene.
BendroflumethiazideThe serum concentration of Bendroflumethiazide can be increased when it is combined with Metixene.
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Metixene.
BezitramideThe risk or severity of adverse effects can be increased when Metixene is combined with Bezitramide.
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Metixene.
Botulinum Toxin Type AMetixene may increase the anticholinergic activities of Botulinum Toxin Type A.
Botulinum Toxin Type BMetixene may increase the anticholinergic activities of Botulinum Toxin Type B.
BuprenorphineThe risk or severity of adverse effects can be increased when Metixene is combined with Buprenorphine.
ButorphanolThe risk or severity of adverse effects can be increased when Metixene is combined with Butorphanol.
CarfentanilThe risk or severity of adverse effects can be increased when Metixene is combined with Carfentanil.
ChlorothiazideThe serum concentration of Chlorothiazide can be increased when it is combined with Metixene.
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Metixene.
ChlorthalidoneThe serum concentration of Chlorthalidone can be increased when it is combined with Metixene.
CimetropiumMetixene may increase the anticholinergic activities of Cimetropium.
CodeineThe risk or severity of adverse effects can be increased when Metixene is combined with Codeine.
CoumaphosThe therapeutic efficacy of Metixene can be decreased when used in combination with Coumaphos.
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Metixene.
DarifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Metixene.
DecamethoniumThe therapeutic efficacy of Metixene can be decreased when used in combination with Decamethonium.
DemecariumThe therapeutic efficacy of Metixene can be decreased when used in combination with Demecarium.
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Metixene.
DexetimideThe risk or severity of adverse effects can be increased when Dexetimide is combined with Metixene.
DextromoramideThe risk or severity of adverse effects can be increased when Metixene is combined with Dextromoramide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Metixene is combined with Dextropropoxyphene.
DezocineThe risk or severity of adverse effects can be increased when Metixene is combined with Dezocine.
DichlorvosThe therapeutic efficacy of Metixene can be decreased when used in combination with Dichlorvos.
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Metixene.
DihydrocodeineThe risk or severity of adverse effects can be increased when Metixene is combined with Dihydrocodeine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Metixene is combined with Dihydroetorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Metixene is combined with Dihydromorphine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Metixene is combined with Diphenoxylate.
DonepezilThe therapeutic efficacy of Metixene can be decreased when used in combination with Donepezil.
DPDPEThe risk or severity of adverse effects can be increased when Metixene is combined with DPDPE.
DronabinolMetixene may increase the tachycardic activities of Dronabinol.
EchothiophateThe therapeutic efficacy of Metixene can be decreased when used in combination with Echothiophate.
EdrophoniumThe therapeutic efficacy of Metixene can be decreased when used in combination with Edrophonium.
EluxadolineMetixene may increase the constipating activities of Eluxadoline.
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Metixene.
EthylmorphineThe risk or severity of adverse effects can be increased when Metixene is combined with Ethylmorphine.
EtorphineThe risk or severity of adverse effects can be increased when Metixene is combined with Etorphine.
FentanylThe risk or severity of adverse effects can be increased when Metixene is combined with Fentanyl.
FenthionThe therapeutic efficacy of Metixene can be decreased when used in combination with Fenthion.
FesoterodineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Metixene.
GalantamineThe therapeutic efficacy of Metixene can be decreased when used in combination with Galantamine.
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Metixene.
Ginkgo bilobaThe therapeutic efficacy of Metixene can be decreased when used in combination with Ginkgo biloba.
Glucagon recombinantThe risk or severity of adverse effects can be increased when Metixene is combined with Glucagon recombinant.
GlycopyrroniumThe risk or severity of adverse effects can be increased when Glycopyrronium is combined with Metixene.
GlycopyrroniumMetixene may increase the anticholinergic activities of Glycopyrronium.
HeroinThe risk or severity of adverse effects can be increased when Metixene is combined with Heroin.
HexamethoniumThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Metixene.
HomatropineThe risk or severity of adverse effects can be increased when Metixene is combined with Homatropine.
Huperzine AThe therapeutic efficacy of Metixene can be decreased when used in combination with Huperzine A.
HydrochlorothiazideThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Metixene.
HydrocodoneThe risk or severity of adverse effects can be increased when Metixene is combined with Hydrocodone.
HydroflumethiazideThe serum concentration of Hydroflumethiazide can be increased when it is combined with Metixene.
HydromorphoneThe risk or severity of adverse effects can be increased when Metixene is combined with Hydromorphone.
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Metixene.
IndapamideThe serum concentration of Indapamide can be increased when it is combined with Metixene.
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Metixene.
IsoflurophateThe therapeutic efficacy of Metixene can be decreased when used in combination with Isoflurophate.
ItoprideThe therapeutic efficacy of Itopride can be decreased when used in combination with Metixene.
KetobemidoneThe risk or severity of adverse effects can be increased when Metixene is combined with Ketobemidone.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Metixene is combined with Levomethadyl Acetate.
LevorphanolThe risk or severity of adverse effects can be increased when Metixene is combined with Levorphanol.
LofentanilThe risk or severity of adverse effects can be increased when Metixene is combined with Lofentanil.
MalathionThe therapeutic efficacy of Metixene can be decreased when used in combination with Malathion.
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Metixene.
MefloquineThe therapeutic efficacy of Metixene can be decreased when used in combination with Mefloquine.
MemantineThe therapeutic efficacy of Metixene can be decreased when used in combination with Memantine.
MethadoneThe risk or severity of adverse effects can be increased when Metixene is combined with Methadone.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Metixene is combined with Methadyl Acetate.
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Metixene.
MethyclothiazideThe serum concentration of Methyclothiazide can be increased when it is combined with Metixene.
MetolazoneThe serum concentration of Metolazone can be increased when it is combined with Metixene.
MianserinMianserin may increase the anticholinergic activities of Metixene.
MinaprineThe therapeutic efficacy of Metixene can be decreased when used in combination with Minaprine.
MirabegronThe risk or severity of adverse effects can be increased when Metixene is combined with Mirabegron.
MorphineThe risk or severity of adverse effects can be increased when Metixene is combined with Morphine.
N-butylscopolammonium bromideThe risk or severity of adverse effects can be increased when N-butylscopolammonium bromide is combined with Metixene.
NabiloneMetixene may increase the tachycardic activities of Nabilone.
NalbuphineThe risk or severity of adverse effects can be increased when Metixene is combined with Nalbuphine.
NeostigmineThe therapeutic efficacy of Metixene can be decreased when used in combination with Neostigmine.
NormethadoneThe risk or severity of adverse effects can be increased when Metixene is combined with Normethadone.
NVA237The risk or severity of adverse effects can be increased when NVA237 is combined with Metixene.
OpiumThe risk or severity of adverse effects can be increased when Metixene is combined with Opium.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Metixene.
OxybutyninThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Metixene.
OxycodoneThe risk or severity of adverse effects can be increased when Metixene is combined with Oxycodone.
OxymorphoneThe risk or severity of adverse effects can be increased when Metixene is combined with Oxymorphone.
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Metixene.
PancuroniumThe risk or severity of adverse effects can be increased when Pancuronium is combined with Metixene.
PentazocineThe risk or severity of adverse effects can be increased when Metixene is combined with Pentazocine.
PentoliniumThe risk or severity of adverse effects can be increased when Pentolinium is combined with Metixene.
PethidineThe risk or severity of adverse effects can be increased when Metixene is combined with Pethidine.
PhysostigmineThe therapeutic efficacy of Metixene can be decreased when used in combination with Physostigmine.
PipecuroniumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Metixene.
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Metixene.
PolythiazideThe serum concentration of Polythiazide can be increased when it is combined with Metixene.
Potassium ChlorideMetixene may increase the ulcerogenic activities of Potassium Chloride.
PramlintidePramlintide may increase the anticholinergic activities of Metixene.
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Metixene.
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Metixene.
PyridostigmineThe therapeutic efficacy of Metixene can be decreased when used in combination with Pyridostigmine.
QuinethazoneThe serum concentration of Quinethazone can be increased when it is combined with Metixene.
QuinidineThe risk or severity of adverse effects can be increased when Quinidine is combined with Metixene.
RamosetronMetixene may increase the constipating activities of Ramosetron.
RemifentanilThe risk or severity of adverse effects can be increased when Metixene is combined with Remifentanil.
RivastigmineThe therapeutic efficacy of Metixene can be decreased when used in combination with Rivastigmine.
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Metixene.
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Metixene.
SecretinThe therapeutic efficacy of Secretin can be decreased when used in combination with Metixene.
SolifenacinThe risk or severity of adverse effects can be increased when Solifenacin is combined with Metixene.
SufentanilThe risk or severity of adverse effects can be increased when Metixene is combined with Sufentanil.
SulpirideThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Metixene.
TacrineThe therapeutic efficacy of Metixene can be decreased when used in combination with Tacrine.
TapentadolThe risk or severity of adverse effects can be increased when Metixene is combined with Tapentadol.
TiotropiumMetixene may increase the anticholinergic activities of Tiotropium.
TiotropiumThe risk or severity of adverse effects can be increased when Tiotropium is combined with Metixene.
TolterodineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Metixene.
TopiramateThe risk or severity of adverse effects can be increased when Metixene is combined with Topiramate.
TramadolThe risk or severity of adverse effects can be increased when Metixene is combined with Tramadol.
TrichlorfonThe therapeutic efficacy of Metixene can be decreased when used in combination with Trichlorfon.
TrichlormethiazideThe serum concentration of Trichlormethiazide can be increased when it is combined with Metixene.
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Metixene.
TrimethaphanThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Metixene.
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Metixene.
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Metixene.
TubocurarineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Metixene.
UmeclidiniumUmeclidinium may increase the anticholinergic activities of Metixene.
UmeclidiniumThe risk or severity of adverse effects can be increased when Metixene is combined with Umeclidinium.
VecuroniumThe risk or severity of adverse effects can be increased when Vecuronium is combined with Metixene.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM1
Uniprot ID:
P11229
Molecular Weight:
51420.375 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Guanyl-nucleotide exchange factor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is inhibition of adenylate cyclase.
Gene Name:
CHRM4
Uniprot ID:
P08173
Molecular Weight:
53048.65 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM5
Uniprot ID:
P08912
Molecular Weight:
60073.205 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
G-protein coupled acetylcholine receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is adenylate cyclase inhibition. Signaling promotes phospholipase C activity, leading to the release of inositol trisphosphate (IP3); this then trigge...
Gene Name:
CHRM2
Uniprot ID:
P08172
Molecular Weight:
51714.605 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM3
Uniprot ID:
P20309
Molecular Weight:
66127.445 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23